Table 3.
HIV disease characteristics and ARV regimen at entry
| Characteristic | Total (N=246) |
|---|---|
| Age at ARV initiation (years), (Median, IQR) | 1.2 (0.7–2.1) |
| Age at ARV initiation (months) | |
| 0–<6 mons | 3 (1%) |
| 6–<12 mons | 105 (43%) |
| 12–<18 mons | 31 (13%) |
| 18–<24 mons | 38 (15%) |
| 24–<30 mons | 35 (14%) |
| 30+ mons | 34 (14%) |
| # years on ARVs prior to entry, (Median, IQR) | 5.6 (4.9–6.6) |
| ARV regimen classification (classes) | |
| NRTI | 1 (0%) |
| NRTI + NNRTI | 78 (32%) |
| NRTI + PI | 165 (67%) |
| PI | 2 (1%) |
| ARV regimen classification (HAART) | |
| HAART w/ PI | 164 (67%) |
| HAART w/out PI | 78 (32%) |
| Non-HAART ARV | 4 (2%) |
| WHO disease stage | |
| Clinical stage I | 38 (15%) |
| Clinical stage II | 58 (24%) |
| Clinical stage III | 137 (56%) |
| Clinical stage IV | 13 (5%) |
| CD4 % (Median, IQR) | 39 (34–43) |
| 0–<15% | 1 (0%) |
| 15%–<25% | 6 (2%) |
| 25%+ | 239 (97%) |
| HIV-1 RNA (cp/ml; Median IQR) | 400 (400–400) |
| <=400 cp/ml | 235 (96%) |
| >400 – 5000 cp/ml | 8 (3%) |
| >5000 cp/ml | 3 (1%) |
| P1060 treatment arm | |
| NVP | 126 (51%) |
| LPV/r | 120 (49%) |
| P1060 strata: NVP Exposed | 86 (35%) |
| HIV subtype | |
| A1 | 24 (10%) |
| C | 192 (84%) |
| D | 11 (5%) |
| R10 | 1 (0%) |
| R43 | 1 (0%) |
| Not reported | 17 |
1 HIV-1 RNA censored at 400 copies/ml regardless of assay used